IJMABHR International Journal of Medical and All Body Health ResearchIJMABHR 2582-8940 Anfo Publication House 439 10.54660/IJMBHR.2024.5.4.261-266 Medicinal Plant Biochemistry Research in Indonesia: Challenges, Opportunities, and an Institutional Roadmap for Higher Education HusinSadam WahyonoPoncojari RahardjantoAbdulkadir Master of Biology Education, Postgraduate Program, Universitas Muhammadiyah Malang, Indonesia 2024 5 4 261 266 04112024 06122024 CC BY-NC-SA 4.0

Indonesia is among the world’s biodiversity-rich countries and has deep traditions of herbal medicine use, including jamu. This creates exceptional opportunities for medicinal plant biochemistry research in higher education—spanning metabolomics, natural products chemistry, bioactivity-guided discovery, and translational development of standardized herbal medicines and phytopharmaceuticals. However, Indonesian medicinal plant biochemistry research also faces persistent constraints: access-and-benefit sharing (ABS) governance and permits, ethical engagement with traditional knowledge, gaps in taxonomy and voucher practices, high chemotype variability across regions and seasons, limited access to advanced analytical instrumentation (LC–MS/MS, NMR), annotation bottlenecks in metabolomics, and challenges in standardization, contamination control, and clinical evidence generation. This article provides a framework synthesis (≤2024) that maps these challenges and opportunities and translates them into practical guidance for universities. We integrate literature on Indonesian herbal medicine development (Elfahmi et al., 2014), plant metabolomics standards (Fiehn, 2002; Sumner et al., 2007; Fernie & Tohge, 2017), natural products dereplication and molecular networking (Wolfender et al., 2019; Qin et al., 2022), ethnopharmacology ethics (Heinrich et al., 2020), global governance of genetic resources (CBD, 2011; Oberthür & Rosendal, 2014), and quality control guidance (WHO, 2011) alongside Indonesian regulatory framing for traditional medicines (BPOM, 2019). Results are presented as two conceptual figures, three implementation tables, and a set of institutional metrics for governance readiness, reproducibility, data stewardship, and translation pathways. We argue that the highest-impact strategy is to treat governance, taxonomy, metadata, and standardization as core research outputs—supported by shared analytical facilities, curated local spectral libraries, and partnerships that enable sustainable sourcing and evidence generation. The paper concludes with a roadmap for Indonesian universities to strengthen medicinal plant biochemistry research quality and maximize societal value.

 IndonesiaMedicinal PlantsPlant BiochemistryJamuMetabolomicsNatural ProductsLC–MS/MSNMRDereplicationNagoya ProtocolAccess and Benefit-SharingStandardizationPhytopharmaceuticalHigher Education References Atanasov AG, Zotchev SB, Dirsch VM, International Natural Product Sciences Taskforce. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200-216. Badan Pengawas Obat dan Makanan Republik Indonesia. Peraturan Badan Pengawas Obat dan Makanan Republik Indonesia No. 32 Tahun 2019 tentang Persyaratan Keamanan dan Mutu Obat Tradisional. Jakarta: Badan POM Republik Indonesia; 2019. Convention on Biological Diversity. Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization. Montreal: Secretariat of the Convention on Biological Diversity; 2011. Elfahmi, Woerdenbag HJ, Kayser O. Jamu: Indonesian traditional herbal medicine towards rational phytopharmacological use. J Herb Med. 2014;4(2):51-73. Fernie AR, Tohge T. The genetics of plant metabolism and metabolomics. Annu Rev Genet. 2017;51:287-310. Fiehn O. Metabolomics—the link between genotypes and phenotypes. Plant Mol Biol. 2002;48(1-2):155-171. Heinrich M, Jalil B, Potocnik T, et al. Best practice in ethnopharmacology and ethnobotany: a review and recommendations. J Ethnopharmacol. 2020;249:112376. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. Oberthür S, Rosendal GK. Global governance of genetic resources: access and benefit sharing after the Nagoya Protocol. New York: Routledge; 2014. Qin GF, Zhang X, Zhu F, et al. MS/MS-based molecular networking: an efficient approach for natural products dereplication. Molecules. 2023;28(1):157. doi:10.3390/molecules28010157 Sumner LW, Amberg A, Barrett D, et al. Proposed minimum reporting standards for chemical analysis. Metabolomics. 2007;3(3):211-221. Swandiny GF, et al. Screening of Indonesian traditional medicinal plants as DPP-IV inhibitors using an ethnopharmacology approach. Arch Pharm Res. 2023;46: [pages not specified in query]. Verpoorte R, Choi YH, Kim HK. NMR -based metabolomics at work in phytochemistry. Phytochem Rev. 2007;6(1):3-14. World Health Organization. Quality control methods for International Journal of Medical and All Body Health Research www.allmedicaljournal.com herbal materials. Geneva: World Health Organization; 2011. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016;15(7):473-484. Wolfender JL, Litaudon M, Touboul D, Queiroz EF. Innovative strategies for natural product dereplication and identification in the metabolomics era. Nat Prod Rep. 2019;36(6):855-868. Yousof NSAM, et al. Molecular networking-based mass spectral identification of metabolites in medicinal plants: application example (Brucea javanica). Fitoterapia. 2024. Copyright and License © The Author(s). Authors retain the copyright of their published articles. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution Non Commercial-Share A like 4.0 International (CC BY-NC-SA 4.0) License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.